Proactive Investors - Run By Investors For Investors

Redx Pharma appoints chief medical officer who will oversee launch of phase I clinical trial of new cancer drug

Dr Andrew Saunders has 25 years in the cancer field and was recruited from Lytix Biopharma
lab
The study of RXC004 will get underway in the coming weeks

Redx Pharma Plc (LON:REDX) has appointed a chief medical officer ahead of the imminent launch of phase I clinical trials of its lead drug.

Dr Andrew Saunders has 25 years in the cancer field and was recruited from Lytix Biopharma, a Norwegian immuno-oncology firm, where he held the same role.

READ: Redx Pharma reborn with lower cost base and multiple shots on goal

He will work with the research and development team at Redx, “fronting” the clinical development of RXC004.

This is a potentially potent small molecule drug called a porcupine inhibitor that targets Wnt pathway.

Chairman Iain Ross said he was “very pleased” to announce Saunders’ appointment.

“He brings to the company a wealth of relevant experience and expertise in the clinical development of oncology drugs,” Ross explained.

“This will be invaluable as the company transforms into a clinical stage company with the anticipated commencement of the first phase I study on lead compound RXC004 in the coming weeks.

"We are very excited by the potential of RXC004 to make a major difference in cancer treatment.

“We intend to progress RXC004 in the clinic both as a monotherapy and in combination with a checkpoint inhibitor. Therefore, we envisage that Andrew's recent experience in immuno-oncology combination trials will be particularly pertinent to the design and execution of future clinical trials with RXC004."

Porcupine inhibitors such as RXC004 are a new and potentially breakthrough method of fighting the killer disease.

READ: Redx reshuffles board and clarifies new strategy ahead of rejoining junior market

They work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness. Kill the stem cells and you have a chance of eradicating the disease completely.

Clinical trials of the new Redx drug commence in the “coming weeks”.

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

pills
November 07 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
cough
October 19 2018
Respiratory syncytial virus causes the common cold, for which there is no effective cure.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use